Stroke propagates bacterial aspiration to pneumonia in a model of cerebral ischemia

Stroke. 2006 Oct;37(10):2607-12. doi: 10.1161/01.STR.0000240409.68739.2b. Epub 2006 Aug 31.

Abstract

Background and purpose: Bacterial pneumonia is the most common cause of death in patients sustaining acute stroke and is believed to result from an increased aspiration. Recently, stroke-induced immunodeficiency was described in a mouse model of cerebral ischemia, which is primarily caused by overactivation of sympathetic nervous system. We tested if stroke-induced immunodeficiency increases the risk of pneumonia after aspiration in a newly developed model of poststroke pneumonia.

Methods: Experimental stroke in mice was induced by occlusion of the middle cerebral artery (MCAO) for 60 minutes. Aspiration pneumonia was induced by intranasal application of 20 microL of a defined suspension of Streptococcus pneumoniae in phosphate-buffered saline 4 or 14 days after MCAO. Treatment comprised moxifloxacin (100 mg/kg body weight, six times every 2 hours after operation) or propranolol (30 mg/kg body weight, immediately before as well as 4 and 8 hours after MCAO). Readout was lung histology and bacterial counts in lung and blood.

Results: Nasal inoculation of only 200 colony-forming units of S. pneumoniae caused severe pneumonia and bacteremia after experimental stroke, whereas 200,000 colony-forming units are needed to induce comparable disease in sham animals. Aspiration pneumonia in stroke animals outlasted acute stroke state but was preventable by beta-adrenoreceptor blockade.

Conclusions: Experimental stroke propagates bacterial aspiration from harmless intranasal colonization to harmful pneumonia. Prevention of infections by beta-adrenoreceptor blockade suggests that immunodepression by sympathetic hyperactivity is essential for progression of bacterial aspiration to pneumonia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Administration, Intranasal
  • Adrenergic beta-Antagonists / therapeutic use
  • Animals
  • Bacteremia / etiology
  • Catecholamines / physiology
  • Disease Progression
  • Disease Susceptibility
  • Female
  • Immunologic Deficiency Syndromes / etiology*
  • Immunologic Deficiency Syndromes / physiopathology
  • Immunologic Deficiency Syndromes / prevention & control
  • Infarction, Middle Cerebral Artery / complications*
  • Infarction, Middle Cerebral Artery / immunology
  • Inhalation*
  • Male
  • Mice
  • Nasal Cavity / microbiology
  • Pneumonia, Bacterial / etiology*
  • Pneumonia, Pneumococcal / etiology
  • Specific Pathogen-Free Organisms
  • Streptococcus pneumoniae
  • Stroke / complications*
  • Stroke / immunology
  • Sympathetic Nervous System / drug effects
  • Sympathetic Nervous System / physiopathology

Substances

  • Adrenergic beta-Antagonists
  • Catecholamines